FBInvestor
Stocks / Mineralys Therapeutics Inc
Institutional Ownership

Mineralys Therapeutics Inc

CUSIP 603170101COMMLYSQ1 2026

13D / 13G Filings
22
Schedule 13D/13G on record
Beneficial Filers
11
Distinct reporting persons
Largest Stake
22.4%
Max % of class reported
Institutional Holders
207
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

22 filings · latest Feb 13, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 13, 2026Catalys Pacific Fund, LP13G/A10.1%8.00MSEC
2Feb 5, 2026Fmr LLC13G6.3%5.02MSEC
3Jan 21, 2026Blackrock, Inc.13G5.2%4.11MSEC
4Sep 8, 2025Samsara Biocapital, L.P.13D/A8.2%SEC
5Sep 8, 2025Ra Capital Management, L.P.13D/A9.9%SEC
6Aug 14, 2025Andera Partners13G/A4.2%2.77MSEC
7Aug 14, 2025Catalys Pacific Fund, LP13G/A13.5%8.98MSEC
8Mar 17, 2025Samsara Biocapital, L.P.13D/A9.1%SEC
9Mar 17, 2025Ra Capital Management, L.P.13D/A9.9%SEC
10Feb 14, 2025Adams Street Partners, LLC13G/A2.3%SEC

12 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Mineralys Therapeutics Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Catalys Pacific, LLC7.90M$214.11M
2Ra Capital Management, L.P.7.69M$208.40M
3 Samsara Biocapital, LLC5.87M$159.05M
4Fmr LLC4.86M$131.69M
5Blackrock, Inc.4.48M$121.41M
6Wellington Management Group LLP3.36M$91.00M
7State Street Corp2.94M$79.53M
8Caligan Partners LP2.77M$75.11M
9Laurion Capital Management LP2.23M$60.47M
10Orbimed Advisors LLC2.05M$55.61M